493 results on '"Perol, M."'
Search Results
2. Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
3. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
4. Prise en charge des CBNPC oligométastatiques synchrones: Management of synchronous non-small oligometastatic lung cancer: update 2023
5. Algorithme thérapeutique des CBNPC sans mutation addictive: Algorithm of NSCLC management outside oncogenic addiction
6. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
7. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
8. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
9. Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne: Advanced stage NSCLC excluding oncogenic addiction: second-line systemic treatments
10. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
11. Efficacité du Pembrolizumab chez des octogénaires traités en première ligne pour un cancer du poumon non à petites cellules, métastatique, PD-L1 ≥ 50%, (étude ESCKEYP–GFPC 05-2018)
12. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
13. Les CBNPC de stades avancés hors addiction oncogénique: les traitements systémiques de deuxième ligne
14. Traitements de première ligne dans les CBNPC avancés, en l’absence d’addiction oncogénique (incluant le traitement de maintenance et les anti-angiogéniques)
15. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
16. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
17. Algorithme thérapeutique des CBNPC sans mutation addictive
18. Stratégies et modalités des immunothérapies : espacement des doses, durée
19. Traitement de 1re ligne des CBNPC métastatiques sans addiction oncogénique: First-line treatment of metastatic NSCLC without oncogenic addiction
20. Chimiothérapie de première ligne incluant le traitement de maintenance et les anti-angiogéniques dans les CBNPC avancés en l’absence d’addiction oncogénique
21. Les essais cliniques princeps en immuno-oncologie dans les cancers broncho-pulmonaires
22. Traitement de première ligne et de maintenance dans les CBNPC avancés en l’absence d’addiction oncogénique
23. Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable: Therapeutic algorithm for NSCLC without actionable molecular abnormalities
24. 78P Final analysis of the French real-world study EVIDENS: Effectiveness, safety & quality of life at 36 months of nivolumab in advanced non-small cell lung cancer (NSCLC)
25. 76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis
26. Traitement de seconde ligne et au-delà des cancers bronchopulmonaires non à petites cellules de stade IV en l’absence d’addiction oncogénique
27. Première ligne des CBNPC avancés sans addiction oncogénique : quel traitement pour quel patient ?: Frontline treatment of advanced NSCLC without oncogenic addiction: which treatment for which patient?
28. Traitement de 1re ligne des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogénique
29. Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne: Advanced stage NSCLC excluding oncogenic addiction: Second-line systemic treatments
30. Traitements systémiques de première ligne dans les CBNPC avancés en l’absence d’addiction oncogénique: Frontline systemic treatment of advanced NSCLC without oncogenic addiction
31. P1.13A.02 Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial.
32. Impact of dose modification of immune-checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.
33. Stratégie de maintenance dans les carcinomes bronchiques non à petites cellules de stade IV
34. P1.12B.10 Dose Adjustments and Exposure-Response Associated with Selpercatinib in Patients with Advanced NSCLC
35. MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study
36. PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
37. PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01
38. LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways
39. 1806P Clinical characteristics and management of small cell lung cancer long survivors
40. 1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
41. 1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
42. 1312P Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01
43. 1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)
44. 1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)
45. 202P The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti-PD-1 treatment in patients with non-small cell lung cancer
46. Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
47. Traitement des CBNPC au stade métastatique. Acquis et bonnes pratiques
48. Choix d'un traitement de maintenance dans les cancers bronchiques non à petites cellules avancés
49. Quelle organisation pour la prise en charge des cancers thoraciques en 2008 ? Résultats d’une enquête sur les pratiques en oncologie thoracique en région Rhône-Alpes
50. The Apolipoprotein E ε4 Allele : Association with Alzheimer’s Disease and Depression in Elderly Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.